Faeth Therapeutics
FTH
30 hedge funds and large institutions have $4.47M invested in Faeth Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 12 closing their positions.
0.04% less ownership
Funds ownership: 0.51% → 0.47% (-0.04%)
23% less funds holding
Funds holding: 39 → 30 (-9)
37% less capital invested
Capital invested by funds: $7.06M → $4.47M (-$2.6M)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$246K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$39.3K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$22.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$20.6K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$189K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$134K |
| 3 |
Millennium Management
New York
|
-$107K |
| 4 |
Renaissance Technologies
New York
|
-$81K |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$78.6K |
FTH Hedge Fund Activity: Q3 2022 in Review
30 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q3 2022, worth a combined $4.47M — down 37% from $7.06M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of FTH and 4 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 6 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $246K. The largest seller was Vanguard Group, cutting an estimated $189K.
- 30 institutional investors held Faeth Therapeutics (FTH) as of Q3 2022, down from 39 in Q2 2022.
- Funds reported $4.47M of Faeth Therapeutics stock for Q3 2022, down 37% quarter-over-quarter.
- 4 funds opened new Faeth Therapeutics positions in Q3 2022 and 12 closed out, a net change of -8 holders.
- The largest Faeth Therapeutics buyer in Q3 2022 was Bridgeway Capital Management, an estimated $246K added.
- The largest Faeth Therapeutics seller in Q3 2022 was Vanguard Group, an estimated $189K sold.
Based on aggregated 13F filings for Q3 2022.